Current global disease control efforts focus largely on attempting to stop pandemics after they have already emerged. This fire brigade approach, which generally involves drugs, vaccines, and behavioral change, has severe limitations. Just as we discovered in the 1960s that it is better to prevent heart attacks then try to treat them, over the next 50 years we will realize that it is better to stop pandemics before they spread and that effort should increasingly be focused on viral forecasting and pandemic prevention.
In this talk, Dr. Brad Schneider will discuss how novel viruses enter into the human population from animals and go on to become pandemics. He will then discuss attempts by his own research group to study this process and attempt to control viruses that have only recently emerged. By creating a global network at the interface of humans and animals, we are working to move viral forecasting from a theoretical possibility to a reality.
About the Speaker
Dr. Brad Schneider is Director of Laboratory Sciences for Metabiota, providing oversight, strategic direction, and management of research, surveillance, and response activities in Africa and Asia. With over 15 years of experience in the field, Dr. Schneider has worked with a broad range of pathogens in a diversity of settings, including some of the most logistically challenging regions of the world. He currently manages international laboratory teams comprising expatriates and local nationals engaged in efforts to deploy modern diagnostic capabilities within host country veterinary and public health systems, while fostering biological safety and international cooperative research.
He employs diplomacy to establish productive international networks between US and host-country partners. Previously, at the Centers for Disease Control (CDC), he gained expertise in a broad spectrum of laboratory and field techniques, aiding in the design of diagnostic assays for detection of possible bioterrorism agents and training to serve as a member of a deployable biological incident response team. He has provided scientific consulting to both the U.S. Government and private sector entities in biodefense, emerging infectious diseases, and outbreak response. Dr. Schneider serves globally in leadership and advisory roles as a member of academic, ethics, review, and editorial boards, and has published over 50 peer-reviewed manuscripts on a diversity of infectious disease topics, including viral, bacterial, and parasitic pathogens.